NextVivo

Palo Alto, United States Founded: 2021 • Age: 5 yrs
Immune-competent human-derived models are developed for drug discovery applications.

About NextVivo

NextVivo is a Healthcare company based in Palo Alto (United States) founded in 2021 by Calvin Kuo, Mark Davis, and Adam Margolin. Immune-competent human-derived models are developed for drug discovery applications. It operates on a HealthTech model. NextVivo has raised $7.9 million across 1 funding round from investors including ARE, Khosla Ventures and Wilson Sonsini Goodrich & Rosati. The company has 8 employees. Its chief executive, as recorded, is Adam Margolin. NextVivo offers products and services including Immune Organoid Technology. Its focus areas include Biotechnology and Drug Development. Its competitors include Vivodyne, Adapsyn and VyantBio; 2 of its 3 listed competitors have raised funding.

Company details

NextVivo is focused on the development of immune organoid technology for drug discovery and therapy testing. Holistic 3D models of healthy and diseased tissues are created, retaining key immune cell interactions. Solutions are applied to generate and test therapies for cancer, infections, and autoimmune disorders within human-derived models. The biotechnology sector is primarily targeted with innovative approaches to improve drug safety and efficacy.

  • Headquarters Palo Alto, United States
  • Employees 8
  • Founders Calvin Kuo, Mark Davis, Adam Margolin
  • Sectors
    Healthcare
  • Website nextvivo.bio
  • Social LinkedIn
Key Metrics
  • Total Equity Funding
    $7.9M (USD)

    in 1 rounds

  • Latest Funding Round
    $7.9M (USD), Series A

    Dec 2021

  • Investors
    ARE

    & 2 more

  • Employee Count
    8

Products & Services of NextVivo

NextVivo offers a comprehensive portfolio of products and services, including Immune Organoid Technology.

Immune Organoid Technology
Biotechnology

Organoids are developed for drug testing and therapy.

Funding Insights of NextVivo

NextVivo has successfully raised a total of $7.9M through 1 strategic funding round. The most recent funding activity was a Series A round of $7.9 million completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $7.9M
  • Total Rounds 1
  • Last Round Series A β€” $7.9M
  • First Round $7.9M

    (Dec 2021)

  • Investors Count 3

All 1 funding rounds of NextVivo with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Dec 2021$7.9MSeries A–Khosla Ventures
Valuation history

3 investors in total: 3 institutional.

Investors in NextVivo

NextVivo has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Khosla Ventures and Wilson Sonsini Goodrich & Rosati.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Early-stage startups are funded by this venture capital firm.
2004khoslaventures.comMenlo Park, United States
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US
1994are.comPasadena, United States
Provider of legal services to technology and life science companies
1961wsgr.comPalo Alto, United States
Premium access

Investor details for NextVivo

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of NextVivo

5 people are tracked at NextVivo (4 in leadership, 1 in team); the tracked headcount is 8.

NameRoleGroup
Calvin Kuo
Co-FounderLeadership
Mark Davis
Co-FounderLeadership
Adam Margolin
Co-Founder & CEOLeadership
Cécile Chartier
Chief Scientific OfficerLeadership
Bhawana Shrestha, Ph.D.
ScientistTeam
Premium access

Complete people profiles for NextVivo

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of NextVivo

2 dated milestones of NextVivo, from founding to its latest funding, stage changes and deals.

  1. Founded NextVivo is founded.
  2. Funding First funding round of $7.9M.

Competitors of NextVivo

NextVivo has 3 listed competitors in our database, 2 of them funded. They include Vivodyne, Adapsyn and VyantBio.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
vivodyne.com2021Philadelphia, United States$117.69M
Developer of AI-based platform for lab-grown human tissues
adapsyn.com2016Hamilton, United States
Provider of computational tools for bacterial metabolomic and genomic data analysis
vyantbio.com1999Cherry Hill, United States$10.5M25
Developer of drug discovery platform
Premium access

Detailed competitors of NextVivo

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Life Sciences Platforms & Tools

3 companies that operate in the same segment as NextVivo (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Medidata is recognized as a leading provider of SaaS solutions for clinical research.
1999New York, New York, United StatesUSD 41.5 M
AI-based solutions for health management are provided.
2015Dallas, Texas, United StatesUSD 2.8 B1,111
Real-world health data is provided for research and decisions.
2012Menlo Park, California, United StatesUSD 259.16 M
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about NextVivo

NextVivo was founded in 2021.

NextVivo is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.

Adam Margolin is the CEO of NextVivo, as recorded in our data. They have also founded this company.

NextVivo is a funded company, having raised a total of $7.9M across 1 funding round to date. The company's 1st funding round was a Series A of $7.9M, raised on Dec 2021.

NextVivo has 8 employees.

NextVivo is focused on the development of immune organoid technology for drug discovery and therapy testing. Holistic 3D models of healthy and diseased tissues are created, retaining key immune cell interactions. Solutions are applied to generate and test therapies for cancer, infections, and autoimmune disorders within human-derived models. The biotechnology sector is primarily targeted with innovative approaches to improve drug safety and efficacy.

NextVivo's top competitors include Vivodyne, Adapsyn and VyantBio.

NextVivo offers Immune Organoid Technology.

NextVivo has 3 investors. Key investors include ARE, Khosla Ventures, and Wilson Sonsini Goodrich & Rosati.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available